tirzepatide injector Mounjaro (Tirzepatide) Injection Pen for Diabetes dependent insulinotropic polypeptide (GIP) and glucagon Tirzepatide Zepbound® - Prefilled Pen

Manganese-induced neurotoxicity: New insights into the triad of protein misfolding, mitochondrial impairment, and neuroinflammation

If semaglutide is the right fit, your program can begin the same visit

SURMOUNT-1 Trial (Tirzepatide for Weight Loss in Adults with Obesity): Duration: 72 weeks (18 months) Participants: Adults with BMI 30+ or 27+ with comorbidities Intervention: Weekly tirzepatide injections + lifestyle counseling Average weight loss results in clinical trials of FDA-approved tirzepatide: Dose-dependent response: Higher doses produced greater weight loss Average range across doses: 15-22% of body weight over 72 weeks For context: A 230-pound person losing 20% would lose approximately 46 pounds Placebo (lifestyle alone): Approximately 3% of body weight Key findings: Weight loss was gradual, not rapid (took a full 72 weeks to reach maximum) Higher doses produced more weight loss (dose-response relationship) Almost everyone lost some weight, but the amount varied dramatically Lifestyle counseling was included (not medication alone) Individual Variation: Why Results Differ The clinical trial averages mask huge individual variation

doi: 10.1038/s41574-021-00607-w

MicroRNA-9 fine-tunes dendritic cell function by suppressing negative regulators in a cell-type-specific manner